Search

Displaying results 1731 - 1740 of 2256 in total
  1. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  2. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over

    Categories: Nonergot-derivative Dopamine Receptor Agonists
  3. Drug

    Tetryzoline

    go.drugbank.com/drugs/DB06764
    Approved

    Tetryzoline is found in a wide array of over-the-counter eye drops, including the most common brand, Visine. … [A231769] Available since the 1950s, tetryzoline is a selective α<sub>1</sub>-receptor agonist [A231774] that is used as an ocular and nasal decongestant.

    Categories: Adrenergic alpha-1 Receptor Agonists
  4. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have

    Categories: Adrenergic alpha-1 Receptor Antagonists
  5. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over

  6. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management

  7. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … however, the selective activity of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor

    Categories: Integrin Receptor Antagonist
  8. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease … Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan].

    Categories: Angiotensin 2 Receptor Blocker, Angiotensin Receptor Antagonists
  9. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. ...

  10. Drug

    Lidocaine

    go.drugbank.com/drugs/DB00281
    ApprovedInvestigationalVet approved

    Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583].

    Mixtures: VIVA Patch, VIVA Patch